Product Description
BAT6021 is an anti-TIGIT mAb candidate with afucosylated modification, resulting in higher level of ADCC activity. TIGIT is an inhibitory immunoglobulin superfamily (IgSF) protein that is highly expressed on the surface of activated NK cell, CD4+ T cell and CD8+ T cell. (Sourced from: https://www.bio-thera.com/plus/list.php?tid=54)
Mechanisms of Action: TIGIT Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biothera
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05120375 |
BAT-6021-001-CR | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2023-04-07 |
88% |
2025-07-19 |
Primary Endpoints|Treatments |
NCT05073484 |
BAT-6021-002-CR | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2023-03-30 |
2% |
2023-10-12 |
Primary Endpoints |
CTR20212463 |
CTR20212463 | P1 |
Unknown |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |